Clinical Trials
913 trialsA Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
TRIDENT-1
Turning Point Therapeutics, Inc.
EVEREST-2
A2 Biotherapeutics Inc.
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
GlaxoSmithKline
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
AbbVie
INDIGO
Boston Scientific Corporation
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Immunome, Inc.
BYQoL-GC
Assistance Publique - Hôpitaux de Paris
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Pfizer
SAFE ESO
University Hospital, Clermont-Ferrand
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
St. Jude Children's Research Hospital
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
St. Jude Children's Research Hospital
ELEVATE
University of Southampton
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Astellas Pharma Inc
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
New Phase Ltd.
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
BioNTech SE
Adaptive Symptom Self-Management Immunotherapy Study
University of Arizona
The Food Environment, Microbial Cysteine Metabolism, and Cancer Disparities
Purdue University
Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
Trishula Therapeutics, Inc.
REACH
Rigshospitalet, Denmark
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
NUMANTIA-2
Nelum Corp
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
EGRET
AstraZeneca
EMPOwer
University of Alberta
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Cancer Research UK
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
Vanderbilt-Ingram Cancer Center
ChefHat-001
BigHat Biosciences, Inc.
OMEC-5
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Alterome Therapeutics, Inc.
Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing
Unity Health Toronto
AxeCan
HealthPartners Institute
Spotlight
Astellas Pharma Inc
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
Indocyanine Green (ICG) Guided Tumor Resection
St. Jude Children's Research Hospital
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
FC-VE
University Hospital, Linkoeping
CARE Tool Study Aim 3
Washington University School of Medicine
CHEMOVES
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
ROWAN
Boston Scientific Corporation
NAVIGATE
Bayer
TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
Suzhou Teligene Ltd.
GRACIE
UNICANCER
Anxiety and Depression Levels in Cancer Patients After Self-Application of EFT (Emotional Freedom Techniques)
Soul Medicine Institute
ATEZOGIST
Centre Leon Berard
CodeBreaK 301
Amgen
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Tyligand Pharmaceuticals (Suzhou) Limited
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines, Inc.